Cirone, P., Andresen, C.J., Eswaraka, J.R., et al. (2014) Patient-Derived Xenografts Reveal Limits to PI3K/mTOR- and MEK-Mediated Inhibition of Bladder Cancer. Cancer Chemotherapy and Pharmacology, 73, 525-538.
https://doi.org/10.1007/s00280-014-2376-1

has been cited by the following article:

• TITLE: A Review of Progress in the Construction and Application of Human-Derived Xenograft Models for Bladder Cancer

  AUTHORS: Hao Huang, Qi Zhao, Chen Gong, Xiaowu Pi, Feng Guo, Jun Li, Ying Xiong

  KEYWORDS: Bladder Cancer, PDX Model, Tumor Transplantation, Preclinical Study

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.10 No.2, February 10, 2022

  ABSTRACT: The patient-derived xenografts (PDX) model is an animal model established by transplanting primary tumors or fresh tumor tissues of patient origin directly into immunodeficient mice, which preserves the heterogeneity and survival microenvironment of the primary tumor and is widely used in preclinical and precision medicine research of tumors. This article reviews the construction of the PDX model of human bladder cancer and the progress of the application of the PDX model in bladder cancer.